Several other equities analysts also recently commented on the stock. Kepler Capital Markets set a €70.00 ($83.33) price target on shares of Stratec Biomedical and gave the company a buy rating in a report on Friday, October 27th. Warburg Research set a €62.00 ($73.81) price target on shares of Stratec Biomedical and gave the company a buy rating in a report on Thursday, October 26th. Deutsche Bank set a €56.00 ($66.67) price target on shares of Stratec Biomedical and gave the company a neutral rating in a report on Tuesday, October 24th. Finally, Oddo Bhf set a €58.00 ($69.05) price target on shares of Stratec Biomedical and gave the company a neutral rating in a report on Monday, October 23rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Stratec Biomedical has an average rating of Hold and a consensus target price of €60.50 ($72.02).
Stratec Biomedical (ETR SBS) opened at €67.74 ($80.64) on Thursday. Stratec Biomedical has a fifty-two week low of €41.30 ($49.17) and a fifty-two week high of €69.85 ($83.15).
Stratec Biomedical Company Profile
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.
Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.